ImageneBio (IMA) Net Income towards Common Stockholders (2020 - 2025)

ImageneBio has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$25.6 million for Q3 2025.

• Net Income towards Common Stockholders for Q3 2025 came in at -$25.6 million, down 314.58% year-over-year; the trailing twelve-month figure through Dec 2025 was -$37.5 million (up 29.92% YoY), and the FY2024 annual result was -$49.2 million, up 27.77% from the prior year.
• Net Income towards Common Stockholders came in at -$25.6 million for Q3 2025 at ImageneBio, down from -$2.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $2.8 million in Q4 2021 to a low of -$25.6 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$14.5 million (2021), against an average of -$13.8 million.
• Across the five-year window, Net Income towards Common Stockholders surged 110.74% in 2021 and plunged 604.0% in 2022, its largest moves.
• ImageneBio's Net Income towards Common Stockholders stood at $2.8 million in 2021, then slumped by 604.0% to -$14.1 million in 2022, then sank by 39.4% to -$19.7 million in 2023, then climbed by 11.06% to -$17.5 million in 2024, then slumped by 46.61% to -$25.6 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$25.6 million (Q3 2025), -$2.8 million (Q2 2025), and -$9.1 million (Q1 2025), per Business Quant data.